Evaluation of the Efficacy and Safety of DW1903 in Patients with Gastritis: A Randomized, Double-Blind, Noninferiority, Multicenter, Phase 3 study

CONCLUSIONS: DW1903 of a low-dose PPI was not inferior to DW1903R1 of H2RA. Thus, lowdose PPI can be a novel option for treating gastritis (ClinicalTrials.gov Identifier: NCT05163756).PMID:37309193 | DOI:10.5009/gnl220446

Source: Gut and Liver - June 13, 2023 Category: Gastroenterology Authors: Jie-Hyun Kim Hwoon-Yong Jung In Kyung Yoo Seon-Young Park Jae Gyu Kim Jae Kyu Sung Jin Seok Jang Gab Jin Cheon Kyoung Oh Kim Tae Oh Kim Soo Teik Lee Kwang Bum Cho Hoon Jai Chun Jong-Jae Park Moo In Park Jae-Young Jang Seong Woo Jeon Jin Woong Cho Dae Hwan Source Type: research